Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 2775-2780

  Soon, Gaik H ^a   Shen, Ping ^b   Yong, Eu Leong ^b   Pham, Paul ^c   Flexner, Charles ^c   Lee, Lawrence ^a,b,c  

^a NATIONAL HEALTHCARE GROUP   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; EFAVIRENZ; RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; SULFONAMIDE;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEPATITIS; HUMAN; HUMAN EXPERIMENT; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NEUROLOGIC DISEASE; NEUROPSYCHIATRIC SYMPTOM; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED;

ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; RITONAVIR; SULFONAMIDES;

EID: 77953742463     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01564-09     Document Type: Article

References (21)

1. Baraldi, E., J. Morales-Ramírez, S. Schneider, A. Stoehr, A. Orani, C. Vanden Abeele, and L. Lavreys. 2009. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naïve HIV-1-infected ARTEMIS patients at week 96, abstr. MOPEB034. Abstr. 5th IAS Conf. HIV Pathog., Treatment, Prevention.
2. Bergshoeff, A. S., P. L. Fraaij, J. Ndagijimana, G. Verweel, N. G. Hartwig, T. Niehues, R. De Groot, and D. M. Burger. 2005. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. J. Acquir. Immune Defic. Syndr. 39:63-68.
3. Boffito, M., D. Miralles, and A. Hill. 2008. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naive and -experienced patients. HIV Clin. Trials 9:418-427.
4. Clifford, D. B., S. Evans, Y. Yang, E. P. Acosta, K. Goodkin, K. Tashima, D. Simpson, D. Dorfman, H. Ribaudo, and R. M. Gulick. 2005. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann. Intern. Med. 143:714-721.
5. Colombo, S., A. Beguin, A. Telenti, J. Biollaz, T. Buclin, B. Rochat, and L. A. Decosterd. 2005. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 819:259-276.
6. D'Avolio, A., M. Siccardi, M. Sciandra, L. Baietto, S. Bonora, L. Trentini, and G. Di Perri. 2007. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 859:234-240.
7. De Meyer, S., H. Azijn, D. Surleraux, D. Jochmans, A. Tahri, R. Pauwels, P. Wigerinck, and M. P. de Bethune. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49:2314-2321.
8. Gatanaga, H., T. Hayashida, K. Tsuchiya, M. Yoshino, T. Kuwahara, H. Tsukada, K. Fujimoto, I. Sato, M. Ueda, M. Horiba, M. Hamaguchi, M. Yamamoto, N. Takata, A. Kimura, T. Koike, F. Gejyo, S. Matsushita, T. Shirasaka, S. Kimura, and S. Oka. 2007. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45:1230-1237.
9. Hammer, S. M., J. J. Eron, Jr., P. Reiss, R. T. Schooley, M. A. Thompson, S. Walmsley, P. Cahn, M. A. Fischl, J. M. Gatell, M. S. Hirsch, D. M. Jacobsen, J. S. Montaner, D. D. Richman, P. G. Yeni, and P. A. Volberding. 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA panel. JAMA 300:555-570.
10. Hariparsad, N., S. C. Nallani, R. S. Sane, D. J. Buckley, A. R. Buckley, and P. B. Desai. 2004. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J. Clin. Pharmacol. 44:1273-1281.
11. Hsu, A., J. Isaacson, S. Brun, B. Bernstein, W. Lam, R. Bertz, C. Foit, K. Rynkiewicz, B. Richards, M. King, R. Rode, D. J. Kempf, G. R. Granneman, and E. Sun. 2003. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47:350-359.
12. Lee, L. S., A. Panchalingam, M. C. Yap, and N. I. Paton. 2004. Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir at 100 milligrams and efavirenz in ethnic Chinese patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 48:4476-4478.
13. Lee, L. S., G. H. Soon, P. Shen, E. L. Yong, C. Flexner, and P. Pham. 2010. Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers. Antivir. Ther. 15:275-279.
14. Marzolini, C., A. Telenti, L. A. Decosterd, G. Greub, J. Biollaz, and T. Buclin. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75. (Pubitemid 32055781)
15. McKeage, K., C. M. Perry, and S. J. Keam. 2009. Darunavir: a review of its use in the management of HIV infection in adults. Drugs 69:477-503.
16. Mills, A. M., M. Nelson, D. Jayaweera, K. Ruxrungtham, I. Cassetti, P. M. Girard, C. Workman, I. Dierynck, V. Sekar, C. V. Abeele, and L. Lavreys. 2009. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 23:1679-1688.
17. Molto, J., J. R. Santos, N. Perez-Alvarez, S. Cedeno, C. Miranda, S. Khoo, L. Else, J. M. Llibre, M. Valle, and B. Clotet. 2008. Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 52:3928-3932.
18. Riddler, S. A., R. Haubrich, A. G. DiRienzo, L. Peeples, W. G. Powderly, K. L. Klingman, K. W. Garren, T. George, J. F. Rooney, B. Brizz, U. G. Lalloo, R. L. Murphy, S. Swindells, D. Havlir, and J. W. Mellors. 2008. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 358:2095-2106.
19. Sekar, V. J., M. De Pauw, K. Marien, M. Peeters, E. Lefebvre, and R. M. Hoetelmans. 2007. Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. Antivir. Ther. 12:509-514.
20. ter Heine, R., C. G. Alderden-Los, H. Rosing, M. J. Hillebrand, E. C. van Gorp, A. D. Huitema, and J. H. Beijnen. 2007. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 21:2505-2514.
21. Zhu, M., S. Kaul, P. Nandy, D. M. Grasela, and M. Pfister. 2009. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob. Agents Chemother. 53:2346-2353.